India Cuts Prices Of 463 Anticancers But Loose Ends Remain
Executive Summary
Prices of over 400 anticancers have been revised downwards in India by the capping of trade margins, but some healthcare activists say that real benefits for patients could still be elusive. Pharma is also required to maintain production volumes in the new scenario – will it pinch?
You may also be interested in...
India Remdesivir Supply Gap May Normalize Soon, But No End To Greed
India generic remdesivir supply situation seen improving soon, with existing players Cipla and Hetero ramping up the antiviral and the arrival of new entrant Mylan. But will that be enough to control black marketing of the investigational COVID-19 therapy? The government is also keeping a close watch on the goings on.
India Remdesivir Black Market: Supply Gap May Normalize Soon, But No End To Greed
India generic remdesivir supply situation seen improving soon, with existing players Cipla and Hetero ramping up the antiviral and the arrival of new entrant Mylan. But will that be enough to control black marketing of the investigational COVID-19 therapy? The government is also keeping a close watch on the goings on.
India Pharma 2020: Trends That Can Change Business Tempo
Scrip delves into some key trends that could play out in 2020 to shape and impact Indian pharmaceutical firms. Keep an eye on opportunities in key markets like China and the US, and on private equity interest in “control deals” and trade margin-related tweaks on the Indian market.